Program
sevasemten
Also written as “Sevasemten”, “Sevasemten Dose 1” and “Sevasemten Dose 2”.
Its studies are mostly in Muscular Dystrophy, Duchenne · Muscular Dystrophies, led by Edgewise Therapeutics.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Edgewise Therapeutics | 93 open or running | phase 2since Mar 14, 2022 | Oct 2, 2020 | Jan 2027phase 2 · NCT05540860 |
Also a collaborator on its studies: medpace-inc and sysnav.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 2, 2020First study: phase 1 study in Muscular Dystrophy, DuchenneFirst studyNCT04585464 · 127 enrolled · United States
- Dec 2, 2021Phase 1 study in Muscular Dystrophy, DuchenneNCT05160415 · 12 enrolled · United States
- Mar 14, 2022Phase 2 study in Muscular Dystrophy, DuchenneNCT05291091 · 244 enrolled · United States, Australia, Belgium and more
- Aug 5, 2022Phase 1 study in Muscular DystrophiesNCT05492734 · 10 enrolled · United States
- Sep 6, 2022Phase 2 study in Muscular Dystrophy, DuchenneNCT05540860 · 76 enrolled · United States
- Feb 7, 2023Phase 1 study in Muscular DystrophiesNCT05730842 · 15 enrolled · United States
- Sep 27, 2023Phase 2 study in Muscular Dystrophy, DuchenneNCT06066580 · 260 planned · United States, Australia, Belgium and more
- Oct 20, 2023Phase 2 study in Muscular Dystrophy, DuchenneNCT06100887 · 43 enrolled · United States
- Feb 13, 2025Phase 1 study in Healthy SubjectsNCT06916897 · 42 enrolled · United States
Ahead
- Jan 2027Primary completion: phase 2 study in Muscular Dystrophy, DuchenneNCT05540860
- Mar 2027Primary completion: phase 2 study in Muscular Dystrophy, DuchenneNCT06100887
- Feb 2031Primary completion: phase 2 study in Muscular Dystrophy, DuchenneNCT06066580
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06916897Healthy Subjects · United States | 1 | Completed | Feb 22, 2025 | 42 |
| NCT06100887Muscular Dystrophy, Duchenne · United States | 2 | Active, not recruiting | Mar 2027 | 43 |
| NCT06066580Muscular Dystrophy, Duchenne · United States, Australia, Belgium and more | 2 | By invitation | Feb 2031 | 260 |
| NCT05730842Muscular Dystrophies · United States | 1 | Completed | Apr 6, 2023 | 15 |
| NCT05540860Muscular Dystrophy, Duchenne · United States | 2 | Active, not recruiting | Jan 2027 | 76 |
| NCT05492734Muscular Dystrophies · United States | 1 | Completed | Aug 19, 2022 | 10 |
| NCT05291091Muscular Dystrophy, Duchenne · United States, Australia, Belgium and more | 2 | Completed | Sep 7, 2026 | 244 |
| NCT05160415Muscular Dystrophy, Duchenne · United States | 1 | Completed | Mar 1, 2024 | 12 |
| NCT04585464Muscular Dystrophy, Duchenne · United States | 1 | Completed | Nov 15, 2021 | 127 |
How it is read
Names in the registry
- “Sevasemten”, 2 entries
- “Sevasemten Dose 1”, 2 entries
- “Sevasemten Dose 2”, 2 entries
- “Sevasemten Dose 3”, 2 entries
- “EDG-5506”, 2 entries
Codes read as this program: EDG5506.
Conditions, from the studies’ own filings
- Muscular Dystrophy, Duchenne, 6 studies
- Muscular Dystrophies, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.